SCHEMBL20705572

SCHEMBL20705572

O=C1/C(=C\C=C\c2ccco2)SC(=S)C1NS(=O)(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.60
▸ MEN1 O00255 11/20 0.60
▸ KMT2A Q03164 11/20 0.60
▸ RECQL P46063 10/20 0.60
▸ USP2 O75604 10/20 0.60
▸ KDM4E B2RXH2 9/20 0.60
▸ BLM P54132 8/20 0.60
▸ MCL1 Q07820 6/20 0.60
▸ APEX1 P27695 6/20 0.60
▸ TDP1 Q9NUW8 5/20 0.60
▸ ATG4B Q9Y4P1 2/20 0.60
▸ MAPK1 P28482 2/20 0.60
▸ PLA2G1B P04054 1/20 0.60
▸ GLA P06280 1/20 0.60
▸ DGKA P23743 1/20 0.60
▸ POLB P06746 10/20 0.45
▸ L3MBTL1 Q9Y468 10/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14680208 0.75 MAPT (1.00) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL29354790 0.75 MAPT (1.00) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL19419943 0.75 MAPT (0.62) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL3893383 0.65 KMT2A (0.77) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL3893385 0.65 KMT2A (0.77) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL26485785 0.63 MAPT (0.65) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL5991599 0.63 MEN1 (0.75) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL26459002 0.62 MAPT (1.00) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL8190580 0.61 POLB (0.57) MAPTMEN1KMT2ARECQLUSP2
SCHEMBL8190582 0.61 POLB (0.57) MAPTMEN1KMT2ARECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA MAPT 1460/4885MEN1 2434/4885KMT2A 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback